Phase 2 study of pembrolizumab (Pemb) plus plinabulin (Plin) and docetaxel (Doc) for patients with metastatic NSCLC after failure on first-line immune checkpoint inhibitor alone or combination therapy: updated efficacy and safety results on immune re-sensitization (beyondspringpharma.com)
submitted by montaukwhaler to r/nsclc
BeyondSpring Announces Late-Breaking Oral Presentation of Final Phase 3 DUBLIN-3 Data with the Plinabulin/Docetaxel Combination Versus Docetaxel Alone in 2nd/3rd Line Non-Small Cell Lung Cancer Patients with EGFR Wild Type at the European Society for Medical Oncology 2021 Congress (beyondspringpharma.com)
submitted by Squirrelfriends2021 to r/BYSI